Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation

Although corticotropin-releasing hormone (CRH) and Fas ligand (FasL) have been documented in ovarian carcinoma, a clear association with tumour progression and immuno-escape has not been established. FasL plays an important role in promoting tumour cells' ability to counterattack immune cells....

Descripción completa

Detalles Bibliográficos
Autores principales: Minas, V, Rolaki, A, Kalantaridou, S N, Sidiropoulos, J, Mitrou, S, Petsas, G, Jeschke, U, Paraskevaidis, E A, Fountzilas, G, Chrousos, G P, Pavlidis, N, Makrigiannakis, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360374/
https://www.ncbi.nlm.nih.gov/pubmed/17667919
http://dx.doi.org/10.1038/sj.bjc.6603918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360374/
https://www.ncbi.nlm.nih.gov/pubmed/17667919
http://dx.doi.org/10.1038/sj.bjc.6603918

Ejemplares similares